Value of circulating cell-free DNA in diagnosis of hepatocelluar carcinoma

World Journal of Gastroenterology

Volumn 19, Issue 20, 2013, Pages 3143-3149

  Chen, Ken ^a   Zhang, Hong ^a   Zhang, Li Na ^a   Ju, Shao Qing ^a   Qi, Jing ^a   Huang, Dong Feng ^a   Li, Feng ^a   Wei, Qun ^a   Zhang, Jing ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

Alu; Branched DNA; Circulating cell free DNA; Diagnosis; Hepatocellular carcinoma

Indexed keywords

ALPHA LEVO FUCOSIDASE; DNA; FETOPROTEIN;

ADULT; AGED; ARTICLE; CHEMOLUMINESCENCE; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MALE; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; YOUDEN INDEX;

EID: 84878239978     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i20.3143     Document Type: Article

References (28)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917 [PMID: 14667750 DOI: 10.1016/ S0140-6736(03)14964-1]
2. Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31: 330-335 [PMID: 10655254 DOI: 10.1002/hep.510310211]
3. Yao DF, Dong ZZ, Yao M. Specific molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2007; 6: 241-247 [PMID: 17548245]
4. Mittra I, Nair NK, Mishra PK. Nucleic acids in circulation: are they harmful to the host? J Biosci 2012; 37: 301-312 [PMID: 22581336 DOI: 10.1007/s12038-012-9192-8]
5. Fluss R, Faraggi D, Reiser B. Estimation of the Youden Index and its associated cutoff point. Biom J 2005; 47: 458-472 [PMID: 16161804 DOI: 10.1002/bimj.200410135]
6. Vlassov VV, Laktionov PP, Rykova EY. Circulating nucleic acids as a potential source for cancer biomarkers. Curr Mol Med 2010; 10: 142-165 [PMID: 20196731 DOI: 10.2174/15665 2410790963295]
7. Galeazzi M, Morozzi G, Piccini M, Chen J, Bellisai F, Fineschi S, Marcolongo R. Dosage and characterization of circulating DNA: present usage and possible applications in systemic autoimmune disorders. Autoimmun Rev 2003; 2: 50-55 [PMID: 12848976 DOI: 10.1016/S1568-9972(02)00101-5]
8. Antonatos D, Patsilinakos S, Spanodimos S, Korkonikitas P, Tsigas D. Cell-free DNA levels as a prognostic marker in acute myocardial infarction. Ann N Y Acad Sci 2006; 1075: 278-281 [PMID: 17108221 DOI: 10.1196/annals.1368.037]
9. Sai S, Ichikawa D, Tomita H, Ikoma D, Tani N, Ikoma H, Kikuchi S, Fujiwara H, Ueda Y, Otsuji E. Quantification of plasma cell-free DNA in patients with gastric cancer. Anticancer Res 2007; 27: 2747-2751 [PMID: 17695442]
10. Pathak AK, Bhutani M, Kumar S, Mohan A, Guleria R. Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem 2006; 52: 1833-1842 [PMID: 16423903 DOI: 10.1373/ clinchem.2005.062893]
11. Lui YY, Woo KS, Wang AY, Yeung CK, Li PK, Chau E, Ruygrok P, Lo YM. Origin of plasma cell-free DNA after solid organ transplantation. Clin Chem 2003; 49: 495-496 [PMID: 12600963 DOI: 10.1373/49.3.495]
12. Chiu RW, Lo YM. Recent developments in fetal DNA in maternal plasma. Ann N Y Acad Sci 2004; 1022: 100-104 [PMID: 15251946 DOI: 10.1196/annals.1318.016]
13. Breitbach S, Tug S, Simon P. Circulating cell-free DNA: an up-coming molecular marker in exercise physiology. Sports Med 2012; 42: 565-586 [PMID: 22694348 DOI: 10.2165/11631 380-000000000-00000]
14. Ziegler A, Zangemeister-Wittke U, Stahel RA. Circulating DNA: a new diagnostic gold mine? Cancer Treat Rev 2002; 28: 255-271 [PMID: 12435372 DOI: 10.1016/ S0305-7372(02)00077-4]
15. Chen H, Sun LY, Zheng HQ, Zhang QF, Jin XM. Total serum DNA and DNA integrity: diagnostic value in patients with hepatitis B virus-related hepatocellular carcinoma. Pathology 2012; 44: 318-324 [PMID: 22531347 DOI: 10.1097/ PAT.0b013e328353a24c]
16. Ren N, Qin LX, Tu H, Liu YK, Zhang BH, Tang ZY. The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepato-cellular carcinoma. J Cancer Res Clin Oncol 2006; 132: 399-407 [PMID: 16502316 DOI: 10.1007/s00432-005-0049-5]
17. Zhou J, Shi YH, Fan J. Circulating cell-free nucleic acids: promising biomarkers of hepatocellular carcinoma. Semin Oncol 2012; 39: 440-448 [PMID: 22846861 DOI: 10.1053/j.seminoncol. 2012.05.013]
18. Iida M, Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, Tamatsukuri S, Ishitsuka H, Uchida K, Terai S, Tokuhisa Y, Sakamoto K, Tamesa T, Miyamoto T, Hamamoto Y, Oka M. Relation between serum levels of cell-free DNA and inflammation status in hepatitis C virus-related hepatocellular carcinoma. Oncol Rep 2008; 20: 761-765 [PMID: 18813815]
19. Tokuhisa Y, Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, Tamatsukuri S, Ishitsuka H, Uchida K, Terai S, Sakamoto K, Tamesa T, Oka M. Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma. Br J Cancer 2007; 97: 1399-1403 [PMID: 17940509 DOI: 10.1038/sj.bjc.6604034]
20. Gu Z, Wang H, Nekrutenko A, Li WH. Densities, length proportions, and other distributional features of repetitive sequences in the human genome estimated from 430 megabases of genomic sequence. Gene 2000; 259: 81-88 [PMID: 11163965 DOI: 10.1016/S0378-1119(00)00434-0]
21. Deininger P. Alu elements: know the SINEs. Genome Biol 2011; 12: 236 [PMID: 22204421 DOI: 10.1186/gb-2011-12-12-236]
22. Andreassen R. [Alu elements in the human genome]. Tidsskr Nor Laegeforen 2004; 124: 2345-2349 [PMID: 15467796]
23. Qi J, Qian C, Shi W, Wu X, Jing R, Zhang L, Wang Z, Ju S. Alubased cell-free DNA: a potential complementary biomarker for diagnosis of colorectal cancer. Clin Biochem 2013; 46: 64-69 [PMID: 22975639 DOI: 10.1016/j.clinbiochem.2012.08.026]
24. Marubashi S, Nagano H, Wada H, Kobayashi S, Eguchi H, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M. Clinical significance of alpha-fetoprotein mRNA in peripheral blood in liver resection for hepatocellular carcinoma. Ann Surg Oncol 2011; 18: 2200-2209 [PMID: 21301972 DOI: 10.1245/s10434-011-1577-7]
25. Ogawa C, Kudo M, Minami Y, Chung H, Kawasaki T. Tumor markers after radiofrequency ablation therapy for hepatocellular carcinoma. Hepatogastroenterology 2008; 55: 1454-1457 [PMID: 18795710]
26. Deugnier Y, David V, Brissot P, Mabo P, Delamaire D, Messner M, Bourel M, Legall JY. Serum alpha-L-fucosidase: a new marker for the diagnosis of primary hepatic carcinoma? Hepatology 1984; 4: 889-892 [PMID: 6207091 DOI: 10.1002/hep.1840040516]
27. Fawzy Montaser M, Amin Sakr M, Omar Khalifa M. Alpha-L-fucosidase as a tumour marker of hepatocellular carcinoma. Arab J Gastroenterol 2012; 13: 9-13 [PMID: 22560818 DOI: 10.1016/j.ajg.2012.03.006]
28. Malaguarnera G, Giordano M, Paladina I, Berretta M, Cappellani A, Malaguarnera M. Serum markers of hepatocellular carcinoma. Dig Dis Sci 2010; 55: 2744-2755 [PMID: 20339916 DOI: 10.1007/s10620-010-1184-7]